
Taiwan and Japan ties just got stronger! Taiwanese biotech company, TLC produced a brand new injection called TLC599, to treat osteoarthritis pain. On Thursday, a partnership ceremony was held with Japanese pharma company, Nippon Zoki. The exclusive licensing agreement between the two companies is worth approximately NT$6.5 billion. The ceremony was attended by Minister of Health and several representatives from the Japan-Taiwan Exchange Association.
Taiwan and Japan’s medical partnership grows stronger. TLC and Nippon Zoki announced a new agreement on the drug TLC599, bringing a new treatment option to treat osteoarthritis pain in Japanese patients.
Several Japan-Taiwan representatives attended the event as well as Taiwan’s Minister of Health Shih Chung-liang. They witnessed the signing of the exclusive licensing agreement which is worth around NT$6.5 billion. This collaboration with a 90-year-old Japanese company will promote the treatment in Japan.
George Yeh
CEO of TLC
Nippon Zoki actually focuses on pain and joints. There’s also a very good sales channel for the product, which will let TLC599 enter the Japanese market faster.
Takafumi Konishi
President & CEO of Nippon Zoki
In Japan’s aging society there are many patients who deeply suffer from osteoarthritis of the knee. We hope that from today onwards, we can use all our efforts to contribute to this field. We want to thank everyone who made this contract signing possible.
The health condition of osteoarthritis doesn’t just affect the elderly; it also affects many middle-aged and young adults. Statistics show that there are over 25 million patients in Japan who are over 40-years-old, from which 8 million experience painful symptoms, which could limit daily walking to basic activities ultimately affecting their quality of life.
George Yeh
CEO of TLC
Japan’s medical market, is around the 10th biggest in the world, so this is a very good benchmark to see if this product could have a breakthrough in European or American markets as well.
The TLC599, beyond relieving pain for patients suffering from osteoarthritis, also promotes transnational cooperation, strengthening ties between Taiwan and Japan.
For more Taiwan news, tune in:
Mon to Fri at 9:30 pm on Channel 152
Tue to Sat at 1 am on Channel 53
#medical #tlc599 #osteoarthritis #TLC #japan #nipponzaki #taiwanmedicine
台日合作新里程碑!台灣生技公司TLC研發出新藥TLC599,治療膝關節炎疼痛症狀,上週四宣布與日本臟器合作,簽下約新台幣65億元的高價合約,推動在日本的獨家開發,合作典禮上包含衛福部長石崇良、日本台灣交流協會多位代表,都親臨現場見證。
台日醫療合作,再邁入新里程碑,TLC與日本臟器舉行新藥TLC599合作典禮暨高層對談,替飽受退化性關節炎疼痛所苦的日本病患,帶來新的治療選擇。
典禮上包含衛福部長石崇良、日本台灣交流協會多位代表,都親臨現場見證,台灣生技公司成功締造,約新台幣65億元的高價合約,與日本近90年的老牌製藥廠,強強聯手,推動新藥在日本的獨家開發。
[[TLC執行長 葉志鴻]]
“日本臟器它其實在於疼痛和關節,也有非常好的一個產品的一個銷售的,一個整個通路,可以讓TLC599可以更快速的加快的腳步,去進入這個日本的這個市場”
[[日本臟器製藥社長 小西崇文]]
“在日本這個邁入高齡化社會的國家,有許多患者深受退化性膝關節炎所苦,我們希望今後能盡最大努力,為這個領域做出貢獻,感謝所有為此次,合約簽訂付出心力的人”
膝關節退化的健康問題,不只困擾長輩,也影響不少中壯年族群,據統計,光40歲以上的日本患者就高達2500多萬人,其中約800萬人更出現疼痛症狀,從日常行走到基本活動都可能受限制,連帶影響生活品質。
[[TLC執行長 葉志鴻]]
“日本的整個的醫療的市場,大概在全球大概佔十趴左右,所以這個也是一個,很好的一個基準去看,就是說未來啊,這一個產品在歐美國家,甚至於其他的地方它有的突破的點”
TLC研發出的TLC599,除了有望為退化性關節炎患者緩解疼痛,透過跨國合作,將持續深化台日交流。
更多新聞內容,請鎖定:
民視台灣台(152頻道)週一至週五晚上9:30
民視新聞台(53頻道)週二至週六凌晨1:00
Related News